Thermo Fisher Scientific Inc. is nearing a deal to acquire Solventum's purification and filtration business for approximately $4.1 billion in cash. This transaction, which is expected to close by the end of 2025, will enhance Thermo Fisher's capabilities in bioproduction and will be integrated into its Life Sciences Solutions segment. The deal is anticipated to be dilutive to Thermo Fisher's adjusted earnings per share by $0.06 in the first year following the acquisition. The announcement of the deal could occur as soon as this week. In related news, Trian Fund Management, which holds a 5% stake in Solventum, is advocating for the company to streamline its operations further by separating its dental and software units, aiming to reduce costs and focus on medical and surgical products. Trian has commended Solventum’s sale of the filtration unit to Thermo Fisher, viewing it as a strategic step towards value creation and future growth.